These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38600796)

  • 1. Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
    Guo L; Xi Y; Li L; Guo K; Wu J; Xu J; Wang Y; Wu G; Si S
    Diabetes Obes Metab; 2024 Jul; 26(7):2979-2983. PubMed ID: 38600796
    [No Abstract]   [Full Text] [Related]  

  • 2. Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
    Pace E; Tingen J
    Am Fam Physician; 2017 Oct; 96(8):540-542. PubMed ID: 29094890
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
    Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
    Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new doses of dulaglutide (Trulicity) for diabetes.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):168. PubMed ID: 33429412
    [No Abstract]   [Full Text] [Related]  

  • 7. Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
    Xiao X; Wang C; Lai X; Zhang B; Gu L; Hou J; Zhou Z
    J Diabetes Investig; 2020 May; 11(3):647-652. PubMed ID: 31758850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.
    Chang KC; Shao SC; Kuo S; Yang CY; Chen HY; Chan YY; Ou HT
    Cardiovasc Diabetol; 2020 Oct; 19(1):172. PubMed ID: 33036617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
    Takase T; Nakamura A; Yamamoto C; Nomoto H; Miya A; Dannoura M; Cho KY; Kurihara Y; Manda N; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 May; 10(3):699-705. PubMed ID: 30076787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
    Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.
    Shi LX; Liu XM; Shi YQ; Li QM; Ma JH; Li YB; Du LY; Wang F; Chen LL
    J Diabetes Investig; 2020 Jan; 11(1):142-150. PubMed ID: 31102326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
    Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
    Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
    Ghosh A; Nair R
    Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.